Aptevo Therapeutics Inc. (APVO)
| Bid | 1.42 |
| Market Cap | 8.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.02M |
| EPS (ttm) | 2680.54 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.2 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.44 |
| Volume | 817,724 |
| Avg. Volume (20D) | 4,371,714 |
| Open | 1.45 |
| Previous Close | 1.45 |
| Day's Range | 1.43 - 1.46 |
| 52-Week Range | 1.32 - 381.10 |
| Beta | 5.87 |
| Ex-Dividend Date | n/a |
About APVO
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for APVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · proactiveinvestors.com
Aptevo Therapeutics shares spike on promising trial results for leukemia therapyAptevo Therapeutics (NASDAQ:APVO) saw its shares jump sharply after the company reported encouraging clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a first-in-class CD123 x CD3...
2 weeks ago · accessnewswire.com
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AMLNo dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for e...
1 month ago · accessnewswire.com
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate CancerBuilds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS...
1 month ago · accessnewswire.com
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business UpdateMipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types ...